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Abstract
Streptococcus pneumoniae (the pneumococcus) is the major cause of bacterial meningitis. The 
mechanisms by which pneumococci from the bloodstream penetrate the blood-brain barrier 
to reach the brain are not fully understood. Receptor-mediated adhesion of the bacteria to 
the brain endothelium is considered a key event leading to meningitis development. The aim 
of this review is to discuss recent advances and perspectives related to the interactions of S. 
pneumoniae with the blood-brain barrier during the events leading to meningitis. Altogether, 
the available data suggest that, by precisely defining the pathways and ligands by which S. 
pneumoniae adheres to specific receptors, it may be possible to interfere with the respective 
mechanisms and develop strategies to prevent or even cure pneumococcal meningitis. 
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Streptococcus pneumoniae, the blood-brain barrier, and 
pneumococcal meningitis
The Gram-positive bacterium Streptococcus pneumoniae (the pneumococcus) is an important 
commensal resident of the human nasopharynx. Although carriage is usually asymptomatic, S. 
pneumoniae can become invasive and spread from the upper respiratory tract to other organs, 
leading to serious diseases such as pneumonia, sepsis, or meningitis [1, 2]. S. pneumoniae is 
the major etiological cause of bacterial meningitis, responsible for two-thirds of meningitis 
cases in Europe and in the USA [3-5]. 
Bacterial meningitis is a disease with high morbidity and mortality worldwide despite the 
implementation of several vaccination programs and antimicrobial agents [3-6]. A major 
route for bacteria to reach the meninges is through the bloodstream [7]. Having reached 
the blood vessels in the brain, bacteria present in the bloodstream have to cross the blood-
brain barrier to enter the brain and cause infection. This view is supported by recent 
immunofluorescent analyses combined with high-resolution confocal microscopy, where 
blood-borne S. pneumoniae was clearly shown to adhere to the brain vascular endothelium 
prior to invasion of the brain [8].
The blood-brain barrier is a specialized vasculature system that separates the brain from 
circulating blood and has critical functions in both protection and nutrient supply of the brain 
[9-11]. Endothelial cells form the layer that lines the interior surface of the blood vessels [12, 
13]. Pathogens can invade the brain only after crossing the endothelial cell layer of the blood-
brain barrier and, therefore, they must develop strategies to pass this barrier. The inflammatory 
features and clinical complications following bacterial meningitis normally observed in 
humans can be reproduced using animal models. Notably, most in vivo models that examine 
the pathophysiology of bacterial meningitis involve the direct injection of pneumococci into 
the brain of mice or rats [14-18]. Administration of bacteria directly into the brain bypasses the 
need for blood-brain barrier translocation. In order to study the interaction of blood-borne 
S. pneumoniae with the brain vascular endothelium in vivo, prior to the onset of meningitis, a 
so-called bacteremia-derived meningitis model was established in recent years [8, 19]. This 
model, where bacteria are injected into the bloodstream instead of the brain, has allowed the 
visualization of successive steps from bacteremia to brain invasion. The aim of the present 
review is to discuss recent advances in our understanding how blood-borne S. pneumoniae 
interacts with the blood-brain barrier endothelium during the events leading up to meningitis, 
and how to use such knowledge to develop new therapeutic strategies to fight the disease.




How bacterial pathogens cross the blood-brain barrier is still subject of debate. Several possible 
mechanisms have been implicated in this process, such as: 1) destruction of the endothelial 
cell layers in case of, for example, Neisseria meningitidis [20]; 2) traversal of the blood-brain 
barrier in between the endothelial cells by disruption of tight junctions in case of group A 
streptococci [21]; and 3) receptor-mediated transcytosis across endothelial and epithelial cell 
layers in case of S. pneumoniae [22, 23]. The view that pneumococci pass the blood-brain 
barrier via transcytosis rather than pericellularly is supported by experiments, showing 
a continuous and homogeneous staining of VE-Cadherin in the brain of infected mice [8]. 
This implies that blood-borne S. pneumoniae does not cause a disruption of the endothelial 
tight junctions. In this context, it should be noted that bacterial pathogens like pneumococci 
have the capability to bind to certain receptors on the plasma membrane of epithelial and 
endothelial cells, and this receptor-mediated binding facilitates bacterial invasion into and 
translocation over human cell layers. The passage of bacterial pathogens across such layers is 
a fundamental step for development of invasive diseases and it is necessary for S. pneumoniae 
to cross the blood-brain barrier to develop bacterial meningitis [22, 23]. 
The platelet-activating factor receptor (PAFR)
The first reported receptor implicated in adhesion to, invasion of, and also transcytosis 
through endothelial cells is the PAFR. PAFR is a G-protein coupled receptor with seven 
transmembrane domains and its natural ligand is the platelet-activating factor (PAF). PAF 
is a mediator in diverse pathologic processes, such as allergy, asthma, septic shock, arterial 
thrombosis, and inflammation [24-26]. Binding of PAF to the PAFR stimulates numerous signal 
transduction pathways including phospholipase C, D, A2, mitogen-activated protein kinases 
(MAPKs), and the phosphatidylinositol-calcium second messenger system [25]. PAFR has been 
proposed to bind S. pneumoniae, thereby facilitating adhesion to, uptake by, and transcytosis 
through endothelial cells leading to invasive disease [23, 27, 28]. However, while in vitro and 
in vivo studies indicate that PAFR is involved in the development of invasive pneumococcal 
disease (IPD), there is so far no unequivocal published evidence that a direct binding 
between S. pneumoniae and PAFR occurs [24]. A recent study suggests that PAFR plays a role 
in pneumococcal adhesion to endothelial cells, even though pneumococci do not directly 
bind to PAFR [29]. After immunofluorescent microscopy analysis, colocalization of PAFR and 
S. pneumoniae was not observed in vivo in mouse brain tissue nor in endothelial cells in vitro. 
Nevertheless, upon blockade of PAFR, adhesion of pneumococci to human endothelial cells 
was significantly reduced, indicating that PAFR most likely has an indirect role in IPD [29]. 
When the PAFR was genetically deleted or chemically inhibited, S. pneumoniae was still able 
to adhere to human cells in vitro, and to cause invasive disease in vivo [23, 27]. 
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The laminin receptor (LR)
The LR is an important molecule involved both in cell adhesion to the basement membrane 
and in signal transduction following this binding event. The LR on endothelial cells was found 
to interact with neurotropic viruses, including Sindbis virus [30], Dengue virus [31], adeno-
associated virus [32], tick-borne encephalitis virus, and Venezuelan equine encephalitis virus 
[33]. LR was identified to be a common receptor for both S. pneumoniae and N. meningitidis 
on the surface of rodent and human brain microvascular endothelial cells [19]. Fluorescent 
beads coated with the pneumococcal choline-binding protein (Cbp) A [34-36] that were 
injected intravascularly into mice adhered to the cerebral endothelium. Pretreatment with 
anti-LR antibody led to an inhibition of the adherence of the CbpA-beads to the endothelium 
in mice, thus suggesting that the LR interacts with the bacteria facilitating translocation of 
intracellular pneumococci across the blood-brain barrier endothelium, from the basolateral 
side of endothelial cells to the brain tissue [19]. 
The poly immunoglobulin receptor (pIgR)
The pIgR transports immunoglobulins across mucosal epithelial barriers (e.g., in the 
respiratory tract) as a first line of defense to antigens from pathogenic bacteria [37-39]. S. 
pneumoniae has been shown to bind to pIgR expressed by human nasopharyngeal epithelial 
cells and this binding facilitates pneumococcal translocation through the nasopharyngeal 
epithelium [22]. When human nasopharyngeal epithelial (Detroit) cells were treated with an 
antibody against pIgR prior to pneumococcal challenge, adherence was reduced [22]. This 
implies that pIgR is functionally involved in pneumococcal adhesion to nasopharyngeal 
epithelium. Furthermore, immunoblotting analyses showed that pneumococcal CbpA binds 
to human pIgR, indicating that CbpA may be required to mediate binding of S. pneumoniae to 
this receptor [22]. PIgR is not only present on the epithelium of the respiratory tract, but can 
also be found on the plasma membrane of endothelial cells, especially brain endothelial cells 
[29]. Due to its presence on the blood-brain barrier endothelium, the possible involvement 
of pIgR in pneumococcal adhesion to brain endothelial cells was recently investigated [29]. 
Notably, immunofluorescent analyses of brain tissue of infected mice showed that most 
pneumococci adhering to the brain vasculature were colocalized with pIgR [29]. Furthermore, 
by incubating pneumococci with human endothelial cell lysates, it was shown that S. 
pneumoniae can directly bind to pIgR [29]. The combined results therefore suggest that pIgR 
is a direct adhesion receptor for S. pneumoniae on the blood-brain barrier endothelium. 
Even though the main route of brain invasion seems to be the bloodstream, pneumococci 
may also reach the brain through skull fractures that tear the dura mater, or directly from 
the nasopharynx. In fact, it was recently reported that S. pneumoniae can transmigrate 
from the nasopharyngeal epithelium to the olfactory nerves that anatomically connect the 
upper respiratory tract with the central nervous system [40]. Although it was not shown 
experimentally, an intriguing hypothesis is that the pIgR on the nasopharyngeal epithelium 
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could mediate the passage of the bacteria from the epithelial cells to the olfactory nerve. 
Clearly, once this passage has occurred the bacteria can travel along the nerve and reach the 
brain.
Platelet endothelial cell adhesion molecule-1 (PECAM-1)
The PECAM-1 (also known as CD31) is a pan-endothelial protein present in the intercellular 
junctions of the endothelial cells, that is involved in leukocyte migration, angiogenesis, and 
integrin activation [41-43]. In particular, the involvement of PECAM-1 in leukocyte-endothelium 
interaction and leukocyte trans-endothelial migration in the vascular system makes PECAM-1 
a key molecule in inflammation and neuroinflammation [43]. Recently, PECAM-1 was 
implicated in gastrointestinal infection caused by Salmonella enterica serovar Typhimurium 
[44], suggesting an active role of PECAM-1 in host-pathogen interactions. This raised the 
question whether PECAM-1 might also play a role in host-pneumococcal interactions. Indeed, 
for the first time it was recently shown that, in brain tissue from intravenously infected 
mice, most pneumococci did colocalize with PECAM-1 [45]. Blockade of PECAM-1 with a 
specific antibody in human brain endothelial cells led to a significant reduction of bacterial 
adhesion, indicating that PECAM-1 is functionally involved in S. pneumoniae adhesion to 
the brain vascular endothelium [45]. Using a biochemical approach, it was demonstrated 
that S. pneumoniae can directly bind PECAM-1 expressed by human endothelial cells [45]. 
Importantly, PECAM-1 colocalized with pIgR on the brain endothelium and, moreover, the two 
receptors directly interacted with each other as demonstrated by co-immunoprecipitation 
experiments suggesting the possible formation of a double receptor that facilitates the 
passage of S. pneumoniae across the blood-brain barrier [45] (Figure 1). Nevertheless, to 
unequivocally demonstrate the joint role of PECAM-1 and pIgR in pneumococcal meningitis, 
S. pneumoniae should be intravenously administered to PECAM-1−/− and pIgR−/− mice. In the 
case of a direct role, as suspected, one would expect that only few bacteria can translocate 
the blood-brain barrier in the knock-out mice. Although current literature still lacks such 
experimental evidence, it was previously shown that adhesion of bacteria to the brain 
vasculature endothelium represents a crucial moment for invasion of meningeal pathogens 
in the brain. In addition, the observation that blood-borne pneumococci colocalize with 
both PECAM-1 and pIgR in vivo strongly indicates that the two receptors jointly facilitate the 
passage of the bacteria from the bloodstream into the brain [29, 45].
Cooperation of PAFR, pIgR and PECAM-1 during pneumococcal 
adhesion to endothelial cells: a new model 
From the current literature [24], it remains unclear what the exact role of PAFR is in IPD. The 
involvement of PAFR in S. pneumoniae adhesion to endothelial cells might well be exerted 
through the binding of PAF or pneumococcal cell wall components to the receptor and 
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the subsequent inflammatory consequences of its activation [24]. Inflammation leads to 
an upregulation of receptors expressed on the plasma membrane of the apical side of the 
cells [7, 27, 46], and PECAM-1 and pIgR may be among them. In the presence of more pIgR 
and PECAM-1, S. pneumoniae has more sites to adhere to on the endothelial cells. It has 
been repeatedly shown that blocking PAFR with a specific antibody or antagonist leads to 
a significant reduction of pneumococcal adhesion to endothelial cells in vitro [23, 27, 29]. We 
therefore hypothesize that, due to PAFR blocking, the upregulation of pIgR and PECAM-1 may 
be prohibited. Possibly, the presence of pneumococci may trigger the autocrine production 
of PAF, directly or indirectly, which activates PAFR, leading to an upregulation of pIgR and 
PECAM-1. This would increase pneumococcal adherence to pIgR and PECAM-1 and, in turn, 
more adherent bacteria would increase the chances of bacterial invasion into the cells (Figure 
1). Whether PAFR activation leads, directly or indirectly, to pIgR-PECAM-1 upregulation 
still remains an open question. Besides PAF, secreted pneumococcal components, such as 
pneumolysin [47, 48] and CbpA, could bind to PAFR and activate this receptor [49]. Clearly, 
this idea still needs to be experimentally validated. Accordingly, an in-depth investigation of 
secreted and surface-attached pneumococcal proteins, including proteomics and structural 
analyses, will be required to identify any protein(s) of S. pneumoniae that could be recognized 
and bound by PAFR. Interesting candidate proteins for such studies were recently identified 
by Pribyl et al. in a proteomics-based survey of the pneumococcal surface-bound and 
Figure 1. Cooperation of platelet-activating receptor (PAFR), pIgR, and PECAM-1 in pneumococcal 
adhesion to endothelial cells: a proposed new model. (A) Under normal physiological conditions, PAFR is 
present on the plasma membrane of endothelial cells in its non-activated state, while pIgR and PECAM-1 are 
forming a double receptor displaying binding sites that can potentially be used as anchors for the adhesion 
of bacterial pathogens. (B) Upon pneumococcal infection, inflammation develops and PAFR is activated by 
pneumococcal components, such as pneumolysin and choline-binding proteins, and PAF. Activation of PAFR 
may lead to the upregulation of pIgR-PECAM-1. This enhanced expression of pIgR-PECAM-1 would make 
more potential binding sites available for Streptococcus pneumoniae and, ultimately, this would lead to 
more pneumococci adhering to endothelial cells, allowing them to enter the brain.
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secreted proteins [50]. An important recent finding was that if pIgR and PECAM-1 are blocked 
simultaneously, pneumococcal adhesion to endothelial cells is reduced even more than when 
the two receptors are blocked individually [45]. Bacteria cannot adhere to pIgR and PECAM-1 
after blocking with their respective antibodies, but PAFR activation may still be possible and 
could thus lead to upregulation of PECAM-1 and pIgR expression. 
Humans deficient in receptors PAFR, pIgR, and PECAM-1 have 
not been identified, but mice survive without them   
Humans deficient in PAFR have not been identified. However, PAFR-/- mice have been 
generated [51]. In PAFR-/- mice, modifications of known angiogenic factors, such as vascular 
endothelial growth factor (VEGF), have not been observed, but a sustained rise of the 
chemokines CXCL2 and CCL2 has been detected, which may compensate for the absence 
of PAFR as an important molecule in maintaining immunological surveillance [52]. These 
findings indicate that the absence of PAFR in mice is compatible with health, although it has 
to be noted that this was observed under controlled conditions. Mice lacking pIgR were of 
normal size and fertility as well, but displayed increased IgG levels in their sera, suggesting a 
triggering of systemic immunity [53]. These findings indicate that absence of pIgR is not lethal 
either, but at the same time it seems that absence of pIgR is sensed as a potential danger 
by the systemic immune system [38, 53]. PECAM-1 is expressed not only by endothelial 
cells, but also by platelets, neutrophils, and macrophages, and its signaling pathways might 
mediate resistance to apoptosis and promote cell survival [41, 42]. Absence of PECAM-1 may 
therefore lead to several cellular dysfunctions. Interestingly, PECAM-1 was reported not to be 
required for embryogenesis, fetal maturation, or fertility in mice, and, furthermore, PECAM-1 
expression on platelets is not essential for platelet-platelet aggregation [54]. PECAM-1-/- 
animals develop normally and do not show any signs of an abnormal physiology under normal 
baseline conditions. However, as the animals age they can develop an autoimmune lupus-like 
syndrome and, when stressed, a variety of abnormal responses have also been noticed. In 
particular, PECAM-1-/- animals exhibited a prolonged bleeding time [55]. Thus, although the 
absence of the PAFR, pIgR, or PECAM-1 receptors did not cause serious problems in mice 
during certain circumstances, dysfunctions and abnormalities due to a lack of these receptors 
cannot be excluded. 
Blockade of S. pneumoniae receptors: a new avenue for the 
prevention and cure of pneumococcal meningitis 
Knowledge on the mechanisms by which the pneumococcus interacts with the blood-brain 
barrier before invading the brain is fundamental in order to develop therapeutic strategies 
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to avoid adhesion of S. pneumoniae to the blood-brain barrier and, thus, invasion of the 
pathogen into the central nervous system. Adhesion of pneumococci to the blood-brain 
barrier is spatiotemporally controlled at different sites throughout the brain, and the local 
immune system in the brain is activated immediately as soon as bacteria in the bloodstream 
interact with the blood-brain barrier [8]. The bacteremia-derived meningitis model is used 
to investigate the interactions of bacteria with the blood-brain barrier, including the events 
preceding meningitis [8, 19, 29, 45]. To study meningitis itself, intracisternal administration of 
bacteria was previously used to induce meningitis in vivo [14-18]. Using this model, neutrophil 
influx into the brain was detected only at 30 hours after challenge, indicating that white 
blood cells can be detected in the brain only at late stages of the disease [14]. A high count of 
white blood cells in the cerebrospinal fluid (CSF) is often used as a clinical test for diagnosis 
of meningitis [56]. Moreover, classic symptoms of meningitis, such as rash, neck stiffness, 
photophobia, severe headache, and impaired consciousness develop late [56-58]. While these 
symptoms represent the classical picture of suspected meningitis, the disease may be already 
at an advanced stage in patients displaying them. Thus, it is not really surprising that, at this 
stage, the risks of brain damage are considerable even if the infection is successfully fought 
with antibiotics. World Health Organization (WHO) data indicate that, even if the disease is 
diagnosed early and adequate treatment is started immediately, 5-10% of the patients will die, 
typically within 24-48 hours after occurrence of the first symptoms. When left untreated, up 
to 50% of the patients may die. In case of recovery, brain damage, hearing loss, or a learning 
disability appears in 10-20% of the survivors (http://www.who.int/topics/meningitis/en/). 
It is therefore crucial to start interventions before bacteria have invaded the brain in order 
to optimize the survival chances of patients and to prevent permanent damage. Treatment 
with antibiotics is the clinically used way to cure meningitis, and routine vaccination against 
pneumococcal infections with the pneumococcal conjugate vaccine (PCV), which is active 
against seven to thirteen common capsular serotypes of this pathogen, has significantly 
reduced the incidence of invasive pneumococcal disease in vaccinated children [59-61]. 
Knowing that PAFR, pIgR, and PECAM-1 mediate the first adhesion of blood-borne S. 
pneumoniae to the vascular endothelium of the blood-brain barrier opens a complementary 
approach to antibiotics and vaccines for curing or preventing pneumococcal meningitis by 
developing therapies that interfere with these receptors. This could, for example, be achieved 
by blocking PAFR, pIgR, and PECAM-1 with specific antibodies which would limit the adhesion 
of pneumococci to the blood-brain barrier and then observing whether the systemic 
administration of blocking antibodies leads to less severe disease symptoms. Alternatively, 
blockade of the receptors can be achieved by using either chemical antagonists, such as, for 
instance, L659989 or WEB2086 previously used to successfully block the PAFR in vitro [24], or 
the pneumococcal proteins that should specifically anchor to the receptors, such as CbpA 
that was reported to bind to pIgR in the respiratory epithelium [22, 62]. Another alternative, 
but technically more challenging approach, is to prevent binding of S. pneumoniae to PAFR, 
pIgR and PECAM-1 on the blood-brain barrier endothelium by blocking the respective ligands 
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on the pneumococcal cell surface with engineered soluble derivatives of these receptors. 
This would have the potential advantage of minimal interference with the physiological 
functions of these three receptors. Such studies could be aided by targeted infection-
imaging approaches, for instance, with positron emission tomography (PET) tracers that bind 
well to S. pneumoniae [63]. However, while blocking of these pneumococcal receptors could 
provide protection against meningitis, it will be crucial to develop strategies to avoid possible 
dysfunctions caused by their blocking before this approach can be implemented in the clinic. 
Based on literature data, mutated PAFR in mice is not likely to cause serious dysfunctions 
[51]. However, mutated pIgR may interfere with the normal transport of immunoglobulins 
across cells. It has been shown that treatment with phorbol myristyl acetate (PMA) activates 
isozymes of protein kinase C (PKC), a downstream protein in the signaling cascade of pIgR 
[64]. This activation stimulates not only pIgR transcytosis, but more generally the pathway 
of a variety of molecules in the transcytotic pathways [64]. Thus, treatment with PMA can 
stimulate cells to use other transcytotic systems and their receptors, in case immunoglobulin 
transfer mediated by pIgR is altered. In this way transport of immunoglobulins can be 
maintained through other transcytotic pathways. Regarding the vascular role of PECAM-1, it is 
important to bear in mind that endothelial cells express a vast range of endothelial adhesion 
factors (such as VECAM-1 and ICAM-1) that perform similar functions as PECAM-1 [65, 66]. 
Therefore, is conceivable that such adhesion molecules could complement for PECAM-1´s role 
in case PECAM-1 is blocked. In principle, it should thus be possible to develop monoclonal 
antibodies blocking the pneumococcal binding site of the PECAM-1 receptor. 
While the blocking of pIgR and PECAM-1 showed only a partial reduction of pneumococcal 
adherence to endothelial cells [45], the blocking of the PAFR, pIgR, and PECAM-1 receptors at 
the same time could be a potential way to completely preclude the adhesion of S. pneumoniae 
to the blood-brain barrier endothelium and, therefore, prevent completely pneumococcal 
invasion into the brain. This, however, remains to be assessed experimentally. Clearly, an 
important advantage of conceivable therapies based on monoclonal antibodies against PAFR, 
pIgR, and PECAM-1 would be that these antibodies need to be administered only as long as 
pneumococci are detectable in the blood. Once these have been fought successfully with 
regular antibiotics, the antibody therapy can be stopped, which will limit possible unwanted 
side effects to a minimum. 
Lastly, it has been demonstrated that pneumococci in the blood can reach and adhere to 
the blood-brain barrier endothelium after which they may invade the brain [8]. Bacteremia is 
present in 20-30% of cases with pneumococcal pneumonia, which can occur when an infection 
of the lungs grows out of control [67-69]. Patients with bacteremia and pneumonia can be 
considered ‘high-risk’ for progression towards brain infection and, for this reason, it could 
be valuable for them to receive innovative treatments that block pneumococcal receptors. 
This would prevent pneumococci from adhering to the blood-brain barrier and invading 
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the brain. Such a treatment would even be of relevance for patients who are hospitalized 
with meningitis as it would still reduce the numbers of bacteria adhering to the blood-brain 
barrier and, in combination with antibiotic therapy, both the blood-borne bacteria and the 
bacteria that have already reached the brain could be eliminated. 
Concluding remarks
What is the ultimate goal of knowing how S. pneumoniae invades the brain? Clearly, if 
pneumococci cannot adhere to endothelial cells, bacterial invasion will most likely be 
prevented. Therefore, by precisely defining the pathways by which S. pneumoniae adheres to 
specific receptors, it may be possible to develop drugs that interfere with these mechanisms 
and to develop strategies to prevent or even cure pneumococcal meningitis, as this still 
remains a very serious disease with high mortality and morbidity worldwide. Judged by 
our current understanding of pneumococcal brain invasion, this is a highly ambitious but 
potentially achievable objective.
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